23
total announcements
CORONA.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 21 Oct 2026
P/E (TTM)
61.8
P/E (Forward)
38.3
EPS (TTM)
₹32.54
52W Low
₹1,336.60
52W High
₹2,292.40
Dividend Yield
0.50%
Price / Book
16.5
Debt / Equity
22.1
Revenue (TTM)
₹1,479 Cr
Gross Margin
80.82%
Operating Margin
18.91%
CORONA Remedies Limited
CORONA Remedies Limited has announced the commencement of commercial production at its EU-GMP approved Women's Hormone manufacturing facility at Bhayla, Ahmedabad, marking a significant milestone in the company's journey towards building globally benchmarked pharmaceutical manufacturing capabilities.
CORONA Remedies Limited
CORONA Remedies Limited has announced the commencement of commercial production at its EU-GMP approved Women's Hormone manufacturing facility at Bhayla, Ahmedabad. The facility has an annual manufacturing capacity of 194 million tablets/capsules and 1.5 million ointments/gels. This marks a significant milestone in the Company's journey towards building globally benchmarked pharmaceutical manufacturing capabilities.
CORONA Remedies Limited
CORONA Remedies Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, effective from July 01, 2026, until 48 hours from the declaration of the unaudited financial results for the first quarter and three months ending on June 30, 2026.